Let's remind ourselves and focus on why we're here...21 Feb 2026 13:13
Key Assets & Strategies
SVN-001 (AUD): Phase 3 in UK/EU.
SVN-002 (AUD): Phase 2b (US, FDA 505(b)(2) pathway).
SVN-SDN-014 (PTSD): Pre-clinical, positive results announced late 2025.
SVN-015 (Addiction/Depression): AI-discovered, NIDA-funded.
ATB
ME